Align Capital Partners-backed Premier Biotech completed the acquisition of National Test Systems.

Align Capital Partners-backed Premier Biotech, a manufacturer of rapid drug testing diagnostic devices, completed the acquisition of National Test Systems, a provider of rapid point-of-care diagnostic testing solutions. Financial terms were not disclosed. “The acquisition marks a pivotal step in our growth journey and bolsters our leadership position across the drug and alcohol testing industry. NTS adds meaningful client depth to our Government and Behavioral Health businesses, complementary point-of-care testing solutions with cross sell potential and a fantastic team to our growing organization. We are thrilled for this partnership,” Matt Michalik Premier Biotech CEO.